Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting [...
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with advanced or metastatic melanoma Additional trial-in-progress poster presentation outlining the details of the ongoing Phase 1/2 trial of OBX-115 in patients with advanced solid tumors CAMBRIDGE, Mass., April 24, 2024 BUSINESS WIRE Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma ( NCT05470283 ), at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago on May 31–June 4.
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol-Myers Squibb (NYSE:BMY) shareholders have endured a 33% loss from investing in the stock a year ago [Yahoo! Finance]Yahoo! Finance
- Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire? [Yahoo! Finance]Yahoo! Finance
- Lykos Therapeutics Strengthens Commercial Organization with Key Hires as it Prepares for Potential Commercial Launch [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb: A Lost Decade? [Seeking Alpha]Seeking Alpha
- FTC plans to recommend a possible criminal case against ex-Pioneer CEO [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 5/3/24 - Form 4
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- BMY's page on the SEC website